Christopher J. Wegerski

526 total citations
16 papers, 120 citations indexed

About

Christopher J. Wegerski is a scholar working on Molecular Biology, Organic Chemistry and Biotechnology. According to data from OpenAlex, Christopher J. Wegerski has authored 16 papers receiving a total of 120 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 5 papers in Organic Chemistry and 3 papers in Biotechnology. Recurrent topics in Christopher J. Wegerski's work include Synthetic Organic Chemistry Methods (3 papers), Marine Sponges and Natural Products (3 papers) and RNA modifications and cancer (3 papers). Christopher J. Wegerski is often cited by papers focused on Synthetic Organic Chemistry Methods (3 papers), Marine Sponges and Natural Products (3 papers) and RNA modifications and cancer (3 papers). Christopher J. Wegerski collaborates with scholars based in United States and Papua New Guinea. Christopher J. Wegerski's co-authors include Phillip Crews, Teatulohi Matainaho, Karen Tenney, C. Edwin Garner, Suramya Waidyanatha, Jacob D. McDonald, Susan Cornell-Kennon, Peggy A. Thompson, Dennis S. France and J. Michael Sanders and has published in prestigious journals such as Blood, Cancer Research and Tetrahedron.

In The Last Decade

Christopher J. Wegerski

16 papers receiving 116 citations

Peers

Countries citing papers authored by Christopher J. Wegerski

Since Specialization

Citations

This map shows the geographic impact of Christopher J. Wegerski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher J. Wegerski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher J. Wegerski more than expected).

Fields of papers citing papers by Christopher J. Wegerski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher J. Wegerski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher J. Wegerski. The network helps show where Christopher J. Wegerski may publish in the future.

Co-authorship network of co-authors of Christopher J. Wegerski

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher J. Wegerski. A scholar is included among the top collaborators of Christopher J. Wegerski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher J. Wegerski. Christopher J. Wegerski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Absorption, single-dose and steady-state metabolism, excretion, and pharmacokinetics of adagrasib, a KRASG12C inhibitor 2024 ·Cancer Chemotherapy and Pharmacology ·Lisa Rahbæk, Cornelius Cilliers, Christopher J. Wegerski, (unknown), Jennifer Otten, Lauren Hargis, Matthew A. Marx, James G. Christensen, Jonathan Q. Tran	2
2	POS0463 A NOVEL, ORAL, ALLOSTERIC INHIBITOR OF TYK2 DEMONSTRATES IN VITRO POTENCY, SELECTIVITY, AND IN VIVO EFFICACY IN MOUSE MODELS OF PSORIASIS 2024 ·Annals of the Rheumatic Diseases ·(unknown), Pamela R. Tsuruda, (unknown), (unknown), Christopher J. Wegerski, K. Srinivasan, Gillian L. Hirst, Neelufar Mozaffarian	2
3	1-Aminomethyl SAR in a novel series of flavagline-inspired eIF4A inhibitors: Effects of amine substitution on cell potency and in vitro PK properties 2021 ·Bioorganic & Medicinal Chemistry Letters ·Christian Nilewski, (unknown), Garrick K. Packard, Alan X. Xiang, Paul A. Sprengeler, Boreth Eam, Sarah Fish, Peggy A. Thompson, Christopher J. Wegerski, (unknown), (unknown), Samuel Sperry, Justin T. Ernst, Siegfried Reich	2
4	Disposition and metabolism of 2′,2′”-Dithiobisbenzanilide in rodents following intravenous and oral administration and dermal application 2020 ·Toxicology Reports ·C. Edwin Garner, Christopher J. Wegerski, Melanie Doyle‐Eisele, Jacob D. McDonald, J. Michael Sanders, Benjamin C. Moeller, Suramya Waidyanatha	1
5	Strategic Diastereoselective C1 Functionalization in the Aza-Rocaglamide Scaffold toward Natural Product-Inspired eIF4A Inhibitors 2020 ·Organic Letters ·Christian Nilewski, (unknown), Alan X. Xiang, Garrick K. Packard, Paul A. Sprengeler, Boreth Eam, Sarah Fish, Peggy A. Thompson, Christopher J. Wegerski, Justin T. Ernst, Siegfried Reich	9
6	Comparative disposition of dimethylaminoethanol and choline in rats and mice following oral or intravenous administration 2019 ·Toxicology and Applied Pharmacology ·Kelly A. Shipkowski, J. Michael Sanders, Jacob D. McDonald, C. Edwin Garner, Melanie Doyle‐Eisele, Christopher J. Wegerski, Suramya Waidyanatha	5
7	Abstract B133: eFT226, a first in class inhibitor of eIF4A1, targets FGFR1/2 and HER2 driven cancers 2019 ·Molecular Cancer Therapeutics ·Peggy A. Thompson, Nathan P. Young, Craig R. Stumpf, Boreth Eam, Vikas Goel, Joan Chen, Sarah Fish, Gregory S. Parker, Adina Gerson‐Gurwitz, (unknown), Eric Sung, Jocelyn Staunton, Gary G. Chiang, Christopher J. Wegerski, Samuel Sperry, Kevin R. Webster, Siegfried Reich	3
8	Metabolism and disposition of 2-hydroxy-4-methoxybenzophenone, a sunscreen ingredient, in Harlan Sprague Dawley rats and B6C3F1/N mice; a species and route comparison 2019 ·Xenobiotica ·Esra Mutlu, C. Edwin Garner, Christopher J. Wegerski, Jacob D. McDonald, Barry Mcintyre, Melanie Doyle‐Eisele, Suramya Waidyanatha	9
9	Disposition of β-N-methylamino-l-alanine (L-BMAA), a neurotoxin, in rodents following a single or repeated oral exposure 2017 ·Toxicology and Applied Pharmacology ·Suramya Waidyanatha, Kristen Ryan, J. Michael Sanders, Jacob D. McDonald, Christopher J. Wegerski, (unknown), C. Edwin Garner	10
10	Abstract PR11: eFT508: An oral, potent and highly selective inhibitor of MNK1 and MNK2, promotes anti-tumor immunity as a monotherapy and in combination with immune checkpoint blockade 2017 ·Cancer Research ·Kevin R. Webster, Vikas Goel, Jocelyn Staunton, (unknown), Gregory S. Parker, Craig R. Stumpf, (unknown), Gary G. Chiang, Christopher J. Wegerski, Samuel Sperry, Joan Chen, Vera Huang, Peggy A. Thompson, Chinh Tran, Justin T. Ernst, Stephen E. Webber, Paul A. Sprengeler, Siegfried Reich	3
11	Abstract 596: eFT508, a potent and highly selective inhibitor of MNK1/2 regulates immune checkpoint and cytokine expression promoting anti-tumor immunity 2017 ·Cancer Research ·Kevin R. Webster, Vikas Goel, Jocelyn Staunton, Craig R. Stumpf, Rajesh Sharma, (unknown), Gregory S. Parker, (unknown), Gary G. Chiang, Christopher J. Wegerski, Samuel Sperry, Vera Huang, Joan W. Chen, Peggy A. Thompson, Chinh Tran, Justin T. Ernst, Paul A. Sprengeler, Siegfried Reich	3
12	eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL) 2015 ·Blood ·Kevin R. Webster, Vikas Goel, (unknown), Gregory S. Parker, Jocelyn Staunton, (unknown), (unknown), Gary G. Chiang, Katti Jessen, Christopher J. Wegerski, Samuel Sperry, Vera Huang, Joan W. Chen, Peggy A. Thompson, James R. Appleman, Stephen E. Webber, Paul A. Sprengeler, Siegfried Reich	20
13	Disposition and Metabolism of Cumene in F344 Rats and B6C3F1 Mice 2010 ·Drug Metabolism and Disposition ·(unknown), Christopher J. Wegerski, Daniel J. Kramer, (unknown), Jacob D. McDonald, Kelly J. Dix, J. Michael Sanders	5
14	Stereochemical challenges in characterizing nitrogenous spiro-axane sesquiterpenes from the Indo-Pacific sponges Amorphinopsis and Axinyssa 2006 ·Tetrahedron ·Christopher J. Wegerski, (unknown), (unknown), Frederick A. Valeriote, Teatulohi Matainaho, Phillip Crews	10
15	A Serendipitous Discovery of Isomotuporin-Containing Sponge Populations of Theonella swinhoei 2006 ·Journal of Natural Products ·Christopher J. Wegerski, (unknown), Karen Tenney, Teatulohi Matainaho, Phillip Crews	25
16	Using a kinase screen to investigate the constituents of the sponge Stelletta clavosa obtained from diverse habitats 2004 ·Bioorganic & Medicinal Chemistry ·Christopher J. Wegerski, Dennis S. France, Susan Cornell-Kennon, Phillip Crews	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact